Suzhou Alphamab Co., Ltd.

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement outside Greater China for ASC22 (Envafolimab) to treat all viral diseases including Hepatitis B. ASC22, also known as KN035, is a first-in-class subcutaneously injected PD-L1 antibody. Oncology indications are under development by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. and an oncology biologic license application ("BLA") of KN035 was submitted to China National Medicine Products Administration (NMPA) in December 2020. Under the terms of this agreement, Ascletis obtained an exclusive and worldwide license outside Greater China from Suzhou Alphamab to develop and commercialize ASC22 for all viral diseases including Hepatitis B. Ascletis will pay Suzhou Alphamab a cash upfront payment and Suzhou Alphamab will be eligible to receive payments from Ascletis on development, regulatory and commercial milestones as well as tiered royalties from the mid-teens to around twenty percent on future sales of ASC22. Suzhou Alphamab will manufacture ASC22 for clinical trials and commercialization of viral indications for Ascletis. Together with the exclusive license agreement in Greater China announced jointly by Ascletis and Suzhou Alphamab on January 14, 2019 (Details referring to press release: ), Ascletis has now obtained a global and exclusive license from Suzhou Alphamab to develop and commercialize ASC22 for all viral diseases including Hepatitis B. Ascletis books sales globally for ASC22 of all viral diseases. ASC22 is the most advanced clinical stage immunotherapy in the world for chronic hepatitis B (CHB) functional cure, i.e. hepatitis B surface antigen (HBsAg) loss, through blocking PD-1/PD-L1 pathway. A Phase IIa clinical trial of ASC22 in CHB patients was completed and the data indicated that there was a trend of dose dependent HBsAg reduction after single dose administration of 0.3, 1.0 or 2.5 mg/kg ASC22. Among three patients receiving 2.5 mg/kg dose, one patient achieved a maximum HBsAg reduction of 1.2 log10 IU/mL during the 12-week follow up. The Phase IIa results will be presented in oral parallel session at The Liver Meeting® 2021 by the American Association for the Study of Liver Diseases (AASLD), one of the world's premier meetings on liver disease and will be held during November 12 to November 15 this year. ASC22 is currently in a Phase IIb clinical trial in China with the entire enrollment of 149 CHB patients completed in July this year and preliminary Phase IIb data indicated that HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group. Jinzi J. Wu, PhD, Founder, Chairman and CEO at Ascletis said, "Suzhou Alphamab is a leading biopharmaceutical company and we're thrilled to partner with it on a global basis. Ascletis is a global leader in antiviral drug development such as Hepatitis B which remains a highly unmet medical need globally. Through the strategic partnership with Alphamab, we are accelerating the global development of ASC22 as a first-in-class HBV immunotherapy with the encouraging Phase IIa and Phase IIb efficacy data as well as the advantage in safety and convenience, and hope to offer a functional cure for Hepatitis B patients soon." About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), a global platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, NASH/PBC, and cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors) to address unmet medical needs both in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis targets those therapeutic areas with unmet medical needs from a global perspective, and efficiently advances the developments of pipelines with an aim of leading in global competition. To date, Ascletis has three marketed products and 18 robust R&D pipelines of drug candidates with global competitiveness, and is actively exploring new therapeutic areas. 1. Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients. (3) Hepatitis C: successfully launched an all-oral regimen of combining ASCLEVIR® and GANOVO® (RDV/DNV regimen). 2. Non-alcoholic Steatohepatitis/Primary Biliary Cholangitis: Gannex, a wholly-owned company of Ascletis, is dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THRβ and FXR, three fixed-dose combinations for NASH and one PBC program targeting FXR. 3. Cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors): a pipeline of oral inhibitors targeting FASN, which plays a key role in cancer lipid metabolism, and a pipeline of oral PD-L1 small molecule next generation immune checkpoint inhibitors. 4. Exploratory Indications: Acne: Following NASH and recurrent GBM, the third indication for ASC40 has been approved to enter Phase 2 clinical trial. View original content: SOURCE Ascletis Pharma Inc. Company Codes: HongKong:1672

Less than two months after raising $60 million — its second venture round in a decade — Alphamab is making the hop for the public markets. In its IPO filing with the Hong Kong stock exchange, the Suzhou-based company describes in more detail a game plan it sketched out in May: Beat down a direct path to market for its two lead bispecifics by running multiple parallel clinical programs, while prepping for the potential commercialization of its subcutaneous PD-L1 and advancing another CTLA-4-based immunosuppressant. The HKEX might not have attracted nearly as many biotech applicants as the Nasdaq amid continued concerns about turbulence, but it has delivered some hefty fortunes for the few that made it. Of the top 10 biopharma IPOs from January to June 2019, as compiled by GEN, half are listed on the HKEX. Hansoh, a pharma conglomerate that pulled its first filing late last year to bring a few more VCs into the fold, topped the chart with $1 billion in proceeds. Alphamab is betting that this buoyant tide will also float its boat. It had been preparing for the IPO as soon as Hong Kong financial regulators greenlighted rule amendments to allow listings of pre-revenue biotechs, spinning out Alphamab Oncology from the rest of the biotech pipeline. With KN046, which targets both PD-L1 and CTLA-4, Alphamab is looking at non-small cell lung cancer, triple-negative breast cancer and esophageal squamous-cell carcinoma; KN026 is designed to treat HER2 expressing solid tumors by hitting two epitopes of the receptor. The plan also calls for the construction of new manufacturing and R&D sites in their home city. Founder and CEO Ting Xu, who also chairs some of the other subsidiaries under Suzhou Alphamab, holds almost half of the oncology biotech via Rubymab. His close affiliates, Xitian Zhang and Chuanxiao Xue, are each in for around 10% while Advantech, PAG Growth and New Pavillion represent the biggest institutional backers at roughly 6% each. Social image: Shutterstock